Compare iShares MSCI South Korea ETF (EWY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI South Korea ETF trades at $166.07, while Neurocrine Biosciences Inc trades at $171.32 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| EWY | NBIX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $180.55 |
52-Week Low | $70.65 | $123.10 |
Market Cap | — | $17.30B |
Enterprise Value | — | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, is trading at $166.48, down 5.93% amid significant volatility in South Korean equities. Technical indicators show a bearish trend with strong selling pressure, while the underlying Kospi Index has experienced sharp declines from recent highs. The ETF remains heavily concentrated in Samsung and SK Hynix, making it highly sensitive to semiconductor and AI market dynamics.
The outlook remains challenging with ongoing volatility in chip stocks and foreign investor selling. While long-term AI demand provides potential upside, current market conditions suggest continued pressure. Key risks include single-stock concentration and global tech sector volatility, requiring careful risk management for investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
